TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Dihydroartemisinin-piperaquine With or Without Primaquine on Gametocytes Plasmodium Falciparum in Mesoendemic Area of Indonesia
Brief Summary: Artemisinin-based combination therapy (ACT) has been known to be controversial for stopping malaria transmission.The addition of primaquine (PQ) - the only drug commercially available that kills mature transmission stage - to such treatments might be necessary to eliminate this stage. A study is conducted to evaluate the efficacy of dihydroartemisinin-piperaquine (DHP) regimens with or without PQ on the sexual and asexual stages of P. falciparum in Sumatra, Indonesia.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Primaquine | Arm Label: Low dose primaquine (PQ1); Type: EXPERIMENTAL; Interventions: Drug: Primaquine | Arm Label: Intermediate dose primaquine (PQ2); Type: EXPERIMENTAL; Interventions: Drug: Primaquine | Arm Label: Reference dose primaquine (PQ-R); Type: ACTIVE_COMPARATOR; Interventions: Drug: Primaquine | Intervention Type: DRUG; Name: Primaquine; Assigned to Arm(s): Intermediate dose primaquine (PQ2), Low dose primaquine (PQ1), Placebo, Reference dose primaquine (PQ-R)
B: Arm Label: dihydroartemisinin-piperaquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: dihydroartemisinin-piperaquine | Arm Label: Dihydroartemisininpiperaquine primaquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: dihydroartemisinin-piperaquine + primaquine | Intervention Type: DRUG; Name: dihydroartemisinin-piperaquine; Assigned to Arm(s): dihydroartemisinin-piperaquine | Intervention Type: DRUG; Name: dihydroartemisinin-piperaquine + primaquine; Assigned to Arm(s): Dihydroartemisininpiperaquine primaquine
C: Arm Label: AM(LT); Type: ACTIVE_COMPARATOR; Interventions: Drug: AM(LT) | Arm Label: AM(FDC); Type: EXPERIMENTAL; Interventions: Drug: AM(FDC) | Arm Label: AL; Type: EXPERIMENTAL; Interventions: Drug: AL | Arm Label: DP; Type: EXPERIMENTAL; Interventions: Drug: DP | Arm Label: AA (FDC); Type: EXPERIMENTAL; Interventions: Drug: AA(FDC) | Intervention Type: DRUG; Name: AM(FDC); Assigned to Arm(s): AM(FDC) | Intervention Type: DRUG; Name: AM(LT); Assigned to Arm(s): AM(LT) | Intervention Type: DRUG; Name: AL; Assigned to Arm(s): AL | Intervention Type: DRUG; Name: DP; Assigned to Arm(s): DP | Intervention Type: DRUG; Name: AA(FDC); Assigned to Arm(s): AA (FDC)
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: sulfadoxine-pyrimethamine (SP) plus artesunate (AS) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: primaquine (PQ) plus SP+AS | Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine (SP) plus artesunate (AS); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: primaquine (PQ) plus SP+AS; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Dihydroartemisinin-piperaquine With or Without Primaquine on Gametocytes Plasmodium Falciparum in Mesoendemic Area of Indonesia
Brief Summary: Artemisinin-based combination therapy (ACT) has been known to be controversial for stopping malaria transmission.The addition of primaquine (PQ) - the only drug commercially available that kills mature transmission stage - to such treatments might be necessary to eliminate this stage. A study is conducted to evaluate the efficacy of dihydroartemisinin-piperaquine (DHP) regimens with or without PQ on the sexual and asexual stages of P. falciparum in Sumatra, Indonesia.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Primaquine | Arm Label: Low dose primaquine (PQ1); Type: EXPERIMENTAL; Interventions: Drug: Primaquine | Arm Label: Intermediate dose primaquine (PQ2); Type: EXPERIMENTAL; Interventions: Drug: Primaquine | Arm Label: Reference dose primaquine (PQ-R); Type: ACTIVE_COMPARATOR; Interventions: Drug: Primaquine | Intervention Type: DRUG; Name: Primaquine; Assigned to Arm(s): Intermediate dose primaquine (PQ2), Low dose primaquine (PQ1), Placebo, Reference dose primaquine (PQ-R)
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: chlorproguanil-dapsone-artesunate, Drug: chlorproguanil-dapsone | Intervention Type: DRUG; Name: chlorproguanil-dapsone-artesunate; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: chlorproguanil-dapsone; Assigned to Arm(s): Arm 1
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg), Drug: Artesunate (day 1,2,3: 4 mg/kg), Drug: Primaquine-base (day 3: 0.75 mg/kg) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo tablets | Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Artesunate (day 1,2,3: 4 mg/kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Primaquine-base (day 3: 0.75 mg/kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo tablets; Assigned to Arm(s): 2
D: Arm Label: dihydroartemisinin-piperaquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: dihydroartemisinin-piperaquine | Arm Label: Dihydroartemisininpiperaquine primaquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: dihydroartemisinin-piperaquine + primaquine | Intervention Type: DRUG; Name: dihydroartemisinin-piperaquine; Assigned to Arm(s): dihydroartemisinin-piperaquine | Intervention Type: DRUG; Name: dihydroartemisinin-piperaquine + primaquine; Assigned to Arm(s): Dihydroartemisininpiperaquine primaquine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Dihydroartemisinin-piperaquine With or Without Primaquine on Gametocytes Plasmodium Falciparum in Mesoendemic Area of Indonesia
Brief Summary: Artemisinin-based combination therapy (ACT) has been known to be controversial for stopping malaria transmission.The addition of primaquine (PQ) - the only drug commercially available that kills mature transmission stage - to such treatments might be necessary to eliminate this stage. A study is conducted to evaluate the efficacy of dihydroartemisinin-piperaquine (DHP) regimens with or without PQ on the sexual and asexual stages of P. falciparum in Sumatra, Indonesia.


Options:
A: Intervention Type: DRUG; Name: Artekin / Coartemther; Assigned to Arm(s): N/A
B: Arm Label: AM(LT); Type: ACTIVE_COMPARATOR; Interventions: Drug: AM(LT) | Arm Label: AM(FDC); Type: EXPERIMENTAL; Interventions: Drug: AM(FDC) | Arm Label: AL; Type: EXPERIMENTAL; Interventions: Drug: AL | Arm Label: DP; Type: EXPERIMENTAL; Interventions: Drug: DP | Arm Label: AA (FDC); Type: EXPERIMENTAL; Interventions: Drug: AA(FDC) | Intervention Type: DRUG; Name: AM(FDC); Assigned to Arm(s): AM(FDC) | Intervention Type: DRUG; Name: AM(LT); Assigned to Arm(s): AM(LT) | Intervention Type: DRUG; Name: AL; Assigned to Arm(s): AL | Intervention Type: DRUG; Name: DP; Assigned to Arm(s): DP | Intervention Type: DRUG; Name: AA(FDC); Assigned to Arm(s): AA (FDC)
C: Arm Label: dihydroartemisinin-piperaquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: dihydroartemisinin-piperaquine | Arm Label: Dihydroartemisininpiperaquine primaquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: dihydroartemisinin-piperaquine + primaquine | Intervention Type: DRUG; Name: dihydroartemisinin-piperaquine; Assigned to Arm(s): dihydroartemisinin-piperaquine | Intervention Type: DRUG; Name: dihydroartemisinin-piperaquine + primaquine; Assigned to Arm(s): Dihydroartemisininpiperaquine primaquine
D: Arm Label: Dihydroartemisin-piperaquine; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisin-piperaquine | Arm Label: Mefloquine + Artesunate (MAS3); Type: ACTIVE_COMPARATOR; Interventions: Drug: Mefloquine + Artesunate | Intervention Type: DRUG; Name: Dihydroartemisin-piperaquine; Assigned to Arm(s): Dihydroartemisin-piperaquine | Intervention Type: DRUG; Name: Mefloquine + Artesunate; Assigned to Arm(s): Mefloquine + Artesunate (MAS3)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-label, Multicenter Trial for the Safety and Efficacy of Intracoronary Adult Human Mesenchymal Stem Cells After Acute Myocardial Infarction
Brief Summary: Early reperfusion strategies in tandem with remarkable advances in drugs and devices for treating myocardial infarction (MI) have contributed to a reduction in early mortality, but cardiovascular disease remains the leading cause of death worldwide. Current management strategies cannot solve the problem of cardiomyocyte loss and consequent progression of heart failure. In this respect, stem-cell therapy has shown potential benefits for repairing the damaged myocardium. Mesenchymal stem cells (MSCs) have been considered to be attractive therapeutic candidates because of their high capacity for replication: paracrine effect: ability to preserve potency: and because they do not cause adverse reactions to allogeneic versus autologous transplants. Intracoronary injection of stem cells seems to be safe, but only one clinical trial using MSCs via the intracoronary route in the setting of acute myocardial infarction (AMI) has been carried out. The investigators therefore assessed the safety and efficacy of intracoronary autologous bone marrow (BM)-derived human MSCs in patients with AMI.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: autologous stem cells | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo suspension | Intervention Type: OTHER; Name: autologous stem cells; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: placebo suspension; Assigned to Arm(s): 2
B: Intervention Type: GENETIC; Name: Intracoronary aotologous stem cell transplantation; Assigned to Arm(s): N/A
C: Arm Label: Treated Group; Type: EXPERIMENTAL; Interventions: Procedure: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation | Intervention Type: PROCEDURE; Name: Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation; Assigned to Arm(s): Control Group, Treated Group
D: Arm Label: Mesenchymal stem cell treatment group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesenchymal stem cell | Arm Label: Control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Control group | Intervention Type: DRUG; Name: Mesenchymal stem cell; Assigned to Arm(s): Mesenchymal stem cell treatment group | Intervention Type: DRUG; Name: Control group; Assigned to Arm(s): Control group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Acceptability and Continuation Rate of Implanon in a Brazilian Public Sector
Brief Summary: The main side-effect of Implanon is the changes induces in bleeding patterns including amenorrhea, infrequent to irregular bleeding and frequent and prolonged bleeding; without any previous symptom and it was characterized as "breakthrough bleeding" (BTB). BTB is the main causes of early discontinuations. Unfortunately, there is no indication to predict prior to insertion what sort of bleeding pattern any individual woman may have after insertion and the proposed treatments were disappointed. Nevertheless, previous studies with other progestin-only contraceptives (including Implanon) provide evidence that the provision of adequate and intensive counseling to potential users and new acceptors about bleeding changes can help to improve method continuation.

The availability of Implanon in the public sector could help in the development of strategies to introduce the method in the public sector network and the training of medical residents.


Options:
A: Arm Label: All participants; Type: OTHER; Interventions: Drug: All participants (Aviane) | Arm Label: Aviane and Portia; Type: ACTIVE_COMPARATOR; Interventions: Drug: Portia | Arm Label: Aviane & Aviane; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aviane | Intervention Type: DRUG; Name: All participants (Aviane); Assigned to Arm(s): All participants | Intervention Type: DRUG; Name: Portia; Assigned to Arm(s): Aviane and Portia | Intervention Type: DRUG; Name: Aviane; Assigned to Arm(s): Aviane & Aviane
B: Arm Label: copper intrauterine device; Type: ACTIVE_COMPARATOR; Interventions: Device: copper-releasing intrauterine device, Device: ENG-releasing implant, Device: LNG-releasing intrauterine system, Device: LNG-IUS | Arm Label: LNG-releasing intrauterine system; Type: ACTIVE_COMPARATOR; Interventions: Device: ENG-releasing implant, Device: LNG-releasing intrauterine system, Device: LNG-IUS | Arm Label: ENG-releasing implant; Type: ACTIVE_COMPARATOR; Interventions: Device: ENG-releasing implant, Device: LNG-releasing intrauterine system, Device: LNG-IUS | Intervention Type: DEVICE; Name: copper-releasing intrauterine device; Assigned to Arm(s): copper intrauterine device | Intervention Type: DEVICE; Name: ENG-releasing implant; Assigned to Arm(s): ENG-releasing implant, LNG-releasing intrauterine system, copper intrauterine device | Intervention Type: DEVICE; Name: LNG-releasing intrauterine system; Assigned to Arm(s): ENG-releasing implant, LNG-releasing intrauterine system, copper intrauterine device | Intervention Type: DEVICE; Name: LNG-IUS; Assigned to Arm(s): ENG-releasing implant, LNG-releasing intrauterine system, copper intrauterine device
C: N/A
D: Arm Label: Immediate implant; Type: EXPERIMENTAL; Interventions: Device: Sino-implant (II) | Arm Label: Delayed implant; Type: ACTIVE_COMPARATOR; Interventions: Device: Sino-implant (II) | Intervention Type: DEVICE; Name: Sino-implant (II); Assigned to Arm(s): Delayed implant, Immediate implant

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Acceptability and Continuation Rate of Implanon in a Brazilian Public Sector
Brief Summary: The main side-effect of Implanon is the changes induces in bleeding patterns including amenorrhea, infrequent to irregular bleeding and frequent and prolonged bleeding; without any previous symptom and it was characterized as "breakthrough bleeding" (BTB). BTB is the main causes of early discontinuations. Unfortunately, there is no indication to predict prior to insertion what sort of bleeding pattern any individual woman may have after insertion and the proposed treatments were disappointed. Nevertheless, previous studies with other progestin-only contraceptives (including Implanon) provide evidence that the provision of adequate and intensive counseling to potential users and new acceptors about bleeding changes can help to improve method continuation.

The availability of Implanon in the public sector could help in the development of strategies to introduce the method in the public sector network and the training of medical residents.


Options:
A: Intervention Type: BEHAVIORAL; Name: Quick start oral contraceptive initiation; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: enhanced initial supply of oral contraception | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: conventional initial supply of oral contraception | Intervention Type: OTHER; Name: enhanced initial supply of oral contraception; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: conventional initial supply of oral contraception; Assigned to Arm(s): 2
C: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Text Messages; Type: EXPERIMENTAL; Interventions: Other: Daily Text Messages | Intervention Type: OTHER; Name: Daily Text Messages; Assigned to Arm(s): Text Messages
D: Arm Label: copper intrauterine device; Type: ACTIVE_COMPARATOR; Interventions: Device: copper-releasing intrauterine device, Device: ENG-releasing implant, Device: LNG-releasing intrauterine system, Device: LNG-IUS | Arm Label: LNG-releasing intrauterine system; Type: ACTIVE_COMPARATOR; Interventions: Device: ENG-releasing implant, Device: LNG-releasing intrauterine system, Device: LNG-IUS | Arm Label: ENG-releasing implant; Type: ACTIVE_COMPARATOR; Interventions: Device: ENG-releasing implant, Device: LNG-releasing intrauterine system, Device: LNG-IUS | Intervention Type: DEVICE; Name: copper-releasing intrauterine device; Assigned to Arm(s): copper intrauterine device | Intervention Type: DEVICE; Name: ENG-releasing implant; Assigned to Arm(s): ENG-releasing implant, LNG-releasing intrauterine system, copper intrauterine device | Intervention Type: DEVICE; Name: LNG-releasing intrauterine system; Assigned to Arm(s): ENG-releasing implant, LNG-releasing intrauterine system, copper intrauterine device | Intervention Type: DEVICE; Name: LNG-IUS; Assigned to Arm(s): ENG-releasing implant, LNG-releasing intrauterine system, copper intrauterine device

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase 2 Trial of Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma
Brief Summary: The goal of this clinical research study is to compare pazopanib to temsirolimus in the treatment of advanced clear-cell renal cell carcinoma. The safety of each drug will also be studied.

Pazopanib is designed to block the growth of blood vessels that supply nutrients needed for tumor growth. This may prevent or slow the growth of cancer cells.

Temsirolimus is designed to block the growth of cancer cells, which may cause cancer cells to die.

This is an investigational study. Pazopanib and temsirolimus are both FDA approved and commercially available for the treatment of kidney cancer. It is investigational to compare the 2 drugs.

Up to 90 patients will be enrolled in this study. All will be enrolled at MD Anderson.


Options:
A: Arm Label: Pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib, Behavioral: Quality of Life Assessment | Arm Label: Temsirolimus; Type: EXPERIMENTAL; Interventions: Drug: Temsirolimus, Behavioral: Quality of Life Assessment, Drug: Benadryl | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Pazopanib | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): Temsirolimus | Intervention Type: BEHAVIORAL; Name: Quality of Life Assessment; Assigned to Arm(s): Pazopanib, Temsirolimus | Intervention Type: DRUG; Name: Benadryl; Assigned to Arm(s): Temsirolimus
B: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon-alfa | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SU011248 | Intervention Type: DRUG; Name: Interferon-alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: SU011248; Assigned to Arm(s): 1
C: Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Arm Label: Pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Pazopanib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib
D: Arm Label: pazopanib followed by sunitinib; Type: EXPERIMENTAL; Interventions: Drug: pazopanib, Drug: sunitinib | Arm Label: sunitinib followed by pazopanib; Type: EXPERIMENTAL; Interventions: Drug: pazopanib, Drug: sunitinib | Intervention Type: DRUG; Name: pazopanib; Assigned to Arm(s): pazopanib followed by sunitinib, sunitinib followed by pazopanib | Intervention Type: DRUG; Name: sunitinib; Assigned to Arm(s): pazopanib followed by sunitinib, sunitinib followed by pazopanib

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Systemic Therapy With or Without Up Front Surgery of the Primary Tumor in Breast Cancer Patients With Distant Metastases at Initial presenTation
Brief Summary: SUBMIT is a clinical trial that intends to answer the question whether up front breast surgery in patients with primary distant metastatic breast cancer will result in an improvement of the 2-year survival compared to the survival achieved with systemic therapy and delayed local treatment or systemic therapy alone.

Randomization will take place immediately after the diagnosis of primary distant metastatic breast cancer. Patients either randomize for up front surgery of the breast tumor (UFS) followed by systemic therapy or for systemic therapy (ST) potentially followed by delayed local treatment of the breast tumor.

The primary endpoint of this trial is the 2-years survival. Quality of life is one of the most important secondary endpoints.


Options:
A: Arm Label: A; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: B; Type: OTHER; Interventions: Procedure: Primary surgery | Intervention Type: PROCEDURE; Name: Primary surgery; Assigned to Arm(s): B
B: Arm Label: Pertuzumab + Trastuzumab + Docetaxel; Type: EXPERIMENTAL; Interventions: Drug: Pertuzumab, Drug: Trastuzumab, Drug: Docetaxel | Arm Label: Placebo + Trastuzumab + Docetaxel; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Trastuzumab, Drug: Docetaxel | Intervention Type: DRUG; Name: Pertuzumab; Assigned to Arm(s): Pertuzumab + Trastuzumab + Docetaxel | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Trastuzumab + Docetaxel | Intervention Type: DRUG; Name: Trastuzumab; Assigned to Arm(s): Pertuzumab + Trastuzumab + Docetaxel, Placebo + Trastuzumab + Docetaxel | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Pertuzumab + Trastuzumab + Docetaxel, Placebo + Trastuzumab + Docetaxel
C: Arm Label: Loco Regional Treatment Arm (LRT); Type: EXPERIMENTAL; Interventions: Procedure: Surgery for breast cancer | Arm Label: No Loco-regional Treatment Arm; Type: ACTIVE_COMPARATOR; Interventions: Other: No Loco-regional treatment | Intervention Type: PROCEDURE; Name: Surgery for breast cancer; Assigned to Arm(s): Loco Regional Treatment Arm (LRT) | Intervention Type: OTHER; Name: No Loco-regional treatment; Assigned to Arm(s): No Loco-regional Treatment Arm
D: Arm Label: Upfront surgery; Type: EXPERIMENTAL; Interventions: Procedure: upfront breast surgery | Arm Label: Systemic therapy; Type: OTHER; Interventions: Other: systemic therapy | Intervention Type: PROCEDURE; Name: upfront breast surgery; Assigned to Arm(s): Upfront surgery | Intervention Type: OTHER; Name: systemic therapy; Assigned to Arm(s): Systemic therapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pilot Study of an Oral Phosphodiesterase Inhibitor (Apremilast) for Atopic Dermatitis in Adults
Brief Summary: The purpose of this study is to obtain preliminary data regarding the safety and tolerability of apremilast in AD to support the design of larger controlled studies.


Options:
A: Intervention Type: BIOLOGICAL; Name: omalizumab; Assigned to Arm(s): N/A
B: Arm Label: 20 mg BID; Type: EXPERIMENTAL; Interventions: Drug: Apremilast | Arm Label: 30 mg BID; Type: EXPERIMENTAL; Interventions: Drug: Apremilast | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): 20 mg BID, 30 mg BID
C: Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo (for Dupilumab) | Arm Label: Dupilumab 300 mg once weekly (qw); Type: EXPERIMENTAL; Interventions: Drug: Dupilumab | Arm Label: Dupilumab 300 mg every 2 weeks (q2w); Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo (for Dupilumab) | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 300 mg every 2 weeks (q2w), Dupilumab 300 mg once weekly (qw) | Intervention Type: DRUG; Name: Placebo (for Dupilumab); Assigned to Arm(s): Dupilumab 300 mg every 2 weeks (q2w), Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Dupilumab) | Arm Label: Dupilumab 300 mg every 2 weeks (q2w); Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo (for Dupilumab) | Arm Label: Dupilumab 300 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 300 mg every 2 weeks (q2w), Dupilumab 300 mg qw | Intervention Type: DRUG; Name: Placebo (for Dupilumab); Assigned to Arm(s): Dupilumab 300 mg every 2 weeks (q2w), Placebo

Answer: B